Tri-Tryp Diseases and The Tri-Tryp Genomes
==========================================

*Trypanosoma brucei*, *Trypanosoma cruzi* and *Leishmania major* are unicellular protozoa of considerable medical importance since they are the etiologic agents of sleeping sickness (African trypanosomiasis), Chagas disease (American trypanosomiasis) and leishmaniasis, respectively. The geographic range of these parasites is determined by their insect vectors: in the case of sleeping sickness, a blood sucking fly of the genus *Glossina*, also known as the tsetse fly, for Chagas disease, a reduviid bug known as the "kissing bug" and for leishmaniasis, a phlebotomine sandfly. While sleeping sickness occurs in sub-Saharan Africa, Chagas disease is prevalent in Latin America. Leishmaniasis is considered to be endemic in 88 countries, 72 of which are developing countries in Asia, South America and Africa. Together, these three parasitic diseases represent a huge burden since approximately 0.5 million people are infected with *T. brucei*, 10 million with *T. cruzi* and an estimated 12 million with different species of Leishmania. In addition to the two human-infective subspecies, *T. brucei gambiense* and *T. b. rhodesiense*, other species and subspecies of African trypanosomes cause the disease known as nagana in domestic animals, imposing a further economic burden on several African countries. Different forms of leishmaniasis are caused by at least 20 leishmanial species: cutaneous leishmaniasis, with an estimated 1.5 million cases, and visceral leishmaniasis, with about 500,000 new cases annually, are the most common. Although control of the arthropod vectors of these diseases is an achievable goal and has been successful against the *T. cruzi* vector in parts of Latin America, the alarming resurgence of sleeping sickness in Africa and of leishmaniasis in parts of Asia and Latin America is a constant reminder of the need for better forms of chemotherapy and prevention of these diseases. More detailed information on African and American trypanosomiasis and the different forms of leishmaniasis, including vector distribution, disease control and treatment protocols can be found at <http://apps.who.int/tdr/>.

*Trypanosoma brucei*, *T. cruzi* and *Leishmania* spp. are hemoflagellates of the family Trypanosomatidae (order Kinetoplastida) that is characterized by the presence of a single flagellum and one mitochondrion containing a unique organelle known as the kinetoplast which contains the mitochondrial DNA ([@b104-gmb-35-1-1]). Each parasite has a complex life cycle that involves humans as one of their various hosts ([Figure 1](#f1-gmb-35-1-1){ref-type="fig"}). As some of the earliest divergent members of the Eukaryotae ([@b47-gmb-35-1-1]), these parasites have peculiar aspects of gene expression, including polycistronic transcription of most of their genomes ([@b73-gmb-35-1-1]), RNA polymerase I-mediated transcription of protein-coding genes ([@b46-gmb-35-1-1]), RNA trans-splicing to generate mature, capped mRNAs ([@b62-gmb-35-1-1]) and extensive RNA editing to generate functional mRNAs transcribed from mito-chondrial genes ([@b48-gmb-35-1-1]). Apart from their medical relevance, these peculiar characteristics make these parasites very interesting models for studying genome evolution and other aspects of genome function. On the other hand, the early evolutionary divergence of these organisms has resulted in biochemical characteristics that are not common in higher eukaryotes, such as enzymes related to antioxidant metabolism ([@b87-gmb-35-1-1]) as well as sterol and glycosylphosphatidylinositol (GPI) biosynthesis ([@b64-gmb-35-1-1]; [@b56-gmb-35-1-1]) that have been exploited as promising drug targets.

Genome sequencing of Tri-Tryp parasites began in the early 90s with the analyses of 518 expressed sequence tags (ESTs) generated from mRNA isolated from bloodstream forms of *T. b. rhodesiense* ([@b39-gmb-35-1-1]). Shortly thereafter, a comparison between EST and genomic sequences showed that sequencing random DNA fragments was as efficient as EST analyses for discovering new genes in the African trypanosome ([@b38-gmb-35-1-1]). In 1996, an EST analysis of cDNA libraries constructed with mRNA from *L. major* promastigotes was published ([@b65-gmb-35-1-1]), and the first EST analysis of *T. cruzi* epimastigote forms was published in 1997 ([@b17-gmb-35-1-1]). During this period, pulsed-field gel electrophoretic analysis of chromosomes and the sequencing of large DNA fragments from cosmid, bacterial artificial chromosome and yeast artificial chromosome libraries were also undertaken to generate physical maps of Tri-Tryp genomes ([@b13-gmb-35-1-1]). In 1999, the sequence of a 257-kilobase region spanning almost the entire chromosome 1 of *L. major* revealed the unusual distribution of protein-coding genes that was later found to be characteristic of all Tri-Tryp genomes. The complete sequence of *L. major* chromosome 1 revealed 79 protein-coding genes, with the first 29 genes all encoded on one DNA strand and the remaining 50 genes encoded on the opposite strand ([@b83-gmb-35-1-1]).

The Tri-Tryp gene organization is reminiscent of bacterial operons, with protein coding genes densely packed within directional clusters in one strand separated by strand switch regions (*i.e.*, changes in the coding strand) ([Figure 2](#f2-gmb-35-1-1){ref-type="fig"}). Experimental evidence suggests that transcription initiates bi-directionally between two divergent gene clusters ([@b71-gmb-35-1-1], [@b72-gmb-35-1-1]) to produce polycistronic pre-mRNAs that are subsequently processed. Remarkably, with the exception of the spliced leader (SL) promoter, no promoter is recognized by RNA polymerase II and only a few transcription factors have been identified ([@b27-gmb-35-1-1]; [@b28-gmb-35-1-1]). Even more surprisingly, although orthologs of all conserved components of the RNA polymerase II complex were identified in the Tri-Tryp genome ([@b51-gmb-35-1-1]), the transcription of some trypanosomatid genes such as VSG (Variant Surface Glycoprotein) and the procyclin genes of *T. brucei,* as well as several exogenous genes transfected into *T. cruzi*, are mediated by RNA polymerase I ([@b46-gmb-35-1-1]). Once the polycistronic pre-mRNA is produced, two coupled reactions (trans-splicing and poly-adenylation) result in mature monocistronic transcripts.

Trans-splicing means that every mature mRNA has an identical capped sequence of 39 nucleotides, known at the spliced leader (SL), at the 5′ end ([@b66-gmb-35-1-1]). Whilst no sequence consensus for polyadenylation or SL addition has been found, several studies have demonstrated that polypyrimidine-rich tracts located within intergenic regions guide SL addition and poly-adenylation, resulting in mature mRNAs ([@b62-gmb-35-1-1]) ([Figure 3](#f3-gmb-35-1-1){ref-type="fig"}). Intergenic sequences involved in the processing of *T. cruzi*, *T. brucei* and *Leishmania* mRNA have been thoroughly investigated by comparing mRNA with genomic sequences, initially using EST databases ([@b11-gmb-35-1-1]; [@b22-gmb-35-1-1]; [@b106-gmb-35-1-1]) and, more recently, using high-throughput RNA-sequencing (RNAseq) ([@b103-gmb-35-1-1]; [@b57-gmb-35-1-1]; [@b86-gmb-35-1-1]). In addition to providing valuable information on the mechanisms of gene expression in these organisms, these analyses also yielded data that allowed the optimization of transfection vectors used to express foreign genes and genetic manipulation in trypanosomatids.

Comparative genomic analyses using the Tri-Tryp sequences have already provided interesting insights into the genetic and evolutionary bases of the distinct and shared lifestyles of these parasites. Probably the most striking finding is that the three genomes display high levels of synteny and share a conserved set of \~6,200 genes, 94% of which are arranged in syntenic directional gene clusters ([@b40-gmb-35-1-1]). Alignment of the deduced protein sequences of the majority of the clusters of orthologous genes across the three organisms reveals an average 57% identity between *T. cruzi* and *T. brucei* and 44% identity between *T. cruzi* and *L. major* that reflected the expected phylogenetic relationships ([@b68-gmb-35-1-1]; [@b47-gmb-35-1-1]; [@b108-gmb-35-1-1]; [@b128-gmb-35-1-1]). The majority of species-specific genes occurs on non-syntenic chromosomes and consists of members of large surface antigen families. Structural RNAs, retroelements and gene family expansion are also often associated with breaks in the conservation of gene synteny ([@b40-gmb-35-1-1]). Multi-gene family expansions are generally species-specific and most pronounced in the *T. cruzi* genome. As discussed below, a number of *T. cruzi* multi-gene families encode surface proteins, such as trans-sialidases, mucin-associated surface proteins (MASP) and mucins TcMUC and GP63 that likely play important roles in host-parasite interactions ([@b36-gmb-35-1-1]; [@b116-gmb-35-1-1]; [@b7-gmb-35-1-1]; [@b8-gmb-35-1-1]). Based on their location in regions of synteny breaks these arrays may be subject to extensive rearrangements during the parasite's evolution and are thus directly associated with the specificities of each of the three parasitic diseases.

The Genetic Diversity of T. Cruzi and the Genomes of Different Parasite Strains
===============================================================================

Chagas disease, caused by *T. cruzi*, is endemic in more than 20 Latin American countries, where an estimated 10 million people are infected and the "domiciliation" of the triatomines exposes at least 90 million individuals to the risk of infection. With no vaccine or effective drug treatment available, the main strategy for control must rely on the prevention of transmission by the insect vectors and blood transfusions. The parasite proliferates in the midgut of several species of a triatomid hematophagous vector. After reaching the insect's hindgut, epimastigote forms differentiate into non-dividing, infective metacyclic trypomastigotes that are excreted in the insect's feces. Trypomastigotes can infect a mammalian host by passing through mucous membranes or skin lesions during feeding by the insect. Once inside the mammalian host, trypomastigotes invade different types of cells where they transform into proliferative intracellular amastigotes. After a number of cell divisions in the host cell cytoplasm, amastigotes differentiate into trypomastigotes that are released into the bloodstream after host cell rupture and, after being taken up by an insect during a blood meal, they start a new cycle ([@b18-gmb-35-1-1]) ([Figure 1](#f1-gmb-35-1-1){ref-type="fig"}). The highly heterogenous *T. cruzi* population consists of a large number of strains with distinct characteristics related to morphology, growth rate, parasitemia curves, virulence, pathogenicity, drug sensitivity, antigenic profile, metacyclogenesis and tissue tropism ([@b21-gmb-35-1-1]).

Despite the broad genetic diversity observed among different strains and isolates, early studies based on different genotyping strategies identified two major lineages in the parasite population, named *T. cruzi* I and *T. cruzi* II ([@b107-gmb-35-1-1]; [@b80-gmb-35-1-1]). These divergent lineages occupy distinct ecological environments, namely, the sylvatic cycle (*T. cruzi* I) and the domestic cycle (*T. cruzi* II) of Chagas disease ([@b134-gmb-35-1-1]), as well as distinct sylvatic host associations ([@b21-gmb-35-1-1]). Further analyses led some authors to propose the sub-division of *T. cruzi* II into five sub-groups: *T. cruzi* IIa, IIb, IIc, IId and IIe ([@b20-gmb-35-1-1]). Phylogenetic analyses of the *T. cruzi* strains became more confusing when additional data indicated the existence of not just two, but three major groups in the *T. cruzi* population, in addition to hybrid strains ([@b78-gmb-35-1-1]; [@b6-gmb-35-1-1]; [@b30-gmb-35-1-1]). After intense debate, in 2009 an international consensus recognized the existence of six major strains, also known as discrete typing units (DTUs) I--VI ([@b135-gmb-35-1-1]) ([Table 1](#t1-gmb-35-1-1){ref-type="table"}). Since Chagas disease spawns a variety of clinical forms, these studies are highly relevant: understanding the genetic variation among strains can potentially explain differences in disease pathogenesis, host preferences and, most importantly, provides essential information for the identification of new drug targets and good antigenic candidates for better diagnosis and vaccine development. For instance, *T. cruzi* II strains and the hybrid strains belonging to *T. cruzi* V and VI are the predominant causes of human disease in South America ([@b135-gmb-35-1-1]), whereas *T. cruzi* I strains are more abundant among wild hosts and vectors. Although detailed analysis of the biological and molecular factors underlying *T. cruzi* population structure and the epidemiology of Chagas disease are beyond the scope of this review, one must keep in mind that the genetic variability found in the *T. cruzi* population is an essential aspect to be considered when analyzing this parasites genome.

CL Brener, a clone derived from a hybrid *T. cruzi* strain belonging to *T. cruzi* VI, was chosen as a reference strain for the initial *T. cruzi* genome project. The hybrid nature of the CL Brener clone became clear only after the genome sequencing had begun, when analyses of nuclear and mitochondrial sequences showed that this strain resulted from a fusion event that had occurred between ancient genotypes corresponding to strains belonging to *T. cruzi* II and III groups ([@b40-gmb-35-1-1]; [@b30-gmb-35-1-1]). Prior to this knowledge, the choice of the clone CL Brener, initially classified as a member of sub-group IIe, was based on five characteristics: (1) it was isolated from the domiciliary vector *Triatoma infestans*, (2) its pattern of infectivity in mice was very well known, (3) it had preferential tropism for heart and muscle cells, (4) it showed a clear acute phase in accidentally infected humans, and (5) it was susceptible to drugs used to treat Chagas disease ([@b133-gmb-35-1-1]). In addition, several genomic studies had previously used this strain for karyotype analyses ([@b16-gmb-35-1-1]) and the generation of physical maps and ESTs from all three stages of the parasite life cycle ([@b23-gmb-35-1-1]; [@b49-gmb-35-1-1]; [@b17-gmb-35-1-1]; [@b118-gmb-35-1-1]; [@b91-gmb-35-1-1]; [@b24-gmb-35-1-1]).

The *T. cruzi* CL Brener haploid genome, estimated to be 55 Mb, was sequenced using the WGS (whole genome shotgun) strategy. Because of its hybrid nature and the high level of allelic polymorphism, a 14X coverage, much higher than the usual 8--10X coverage, was required to distinguish the ambiguities derived from allelic variations from those produced by sequencing errors. In contrast to the other two Tri-Tryp genomes, the *T. cruzi* draft sequence ([@b41-gmb-35-1-1]) was published as an assembly of 5,489 scaffolds built by 8,740 contigs. Four years later, based on synteny maps for the *T. brucei* chromosomes, [@b122-gmb-35-1-1] assembled the *T. cruzi* contigs and scaffolds initially in 11 pairs of homologous "*T. brucei*-like" chromosomes and, ultimately, in 41 *T. cruzi* chromosomes. Since trypanosomatid chromosomes do not condensate during mitosis and are therefore not visualized in metaphasic cells the predicted number of *T. cruzi* chromosomes was based on studies of pulsed-field gel electrophoresis (PFGE) analyses ([@b16-gmb-35-1-1]), which turned out to be similar to the number of assembled chromosomes. As mentioned above, the genome organization in *T. cruzi* is largely syntenic with the other Tri-Tryp (*T. brucei* and *L. major*) genomes, with most species-specific genes, such as surface protein gene families, occurring in internal and subtelomeric regions of non-syntenic chromosome ([@b40-gmb-35-1-1]).

Because of its hybrid nature, the CL Brener genome is represented by a redundant dataset since homologous regions displaying a high level of polymorphism were assembled separately, generating two set of contigs, each corresponding to one haplotype. To identify the two haplotypes, reads from the genome of the cloned Esmeraldo strain, a member of *T. cruzi* II, and representing one of the CL Brener parental strain ([@b30-gmb-35-1-1]), were generated. Thus, in the annotation data of the CL Brener genome, the two haplotypes are referred to as "Esmeraldo-like" or "non-Esmeraldo-like" sequences ([@b5-gmb-35-1-1]).

The haploid CL Brener genome has an estimated 12,000 genes. As with the other Tri-Tryps, the *T. cruzi* genes are organized in long polycistronic clusters that are transcribed by RNA polymerase II and processed into monocistronic mRNAs that accumulate differentially during the various stages of the parasite life cycle. As indicated before, one of the main characteristics revealed by the complete sequence of the *T. cruzi* genome was the dramatic expansion of families encoding surface proteins ([@b40-gmb-35-1-1]). Compared to *T. brucei* and *L. major*, *T. cruzi* has the largest set of multi-gene families, perhaps because of its unique capacity to invade and multiply within different types of host cells. Long terminal repeat (LTR) and non-LTR retroelements and other sub-telomeric also contribute to the large proportion of repetitive sequences (50% of the genome) in this genome. The largest protein gene family encodes a group of surface proteins known as trans-sialidases (TS), with 1,430 members. TSs are surface molecules identified as virulent factors of *T. cruzi* that are responsible for transferring sialic acid from host sialogly-coconjugates to the terminal ß-galactose on *T. cruzi* mucins. Mucin-associated surface proteins (MASP) are the second largest *T. cruzi* gene family, with a total of 1,377 members. Although MASP sequences correspond to \~6% of the parasite diploid genome, they were only identified during annotation of the *T. cruzi* genome. MASPs are glycosylphosphatidylinositol (GPI)-anchored surface proteins that are preferentially expressed in trypomastigotes; these proteins are characterized by highly conserved N- and C-terminal domains and a strikingly variable and repetitive central region ([@b8-gmb-35-1-1]). Together with the mucin and GP63 gene families, these four gene families account for \~17% of all protein-coding genes and are organized as dispersed clusters of tandem and interspersed repeats.

Other large families consist of the previously described RHS and DGF-1 genes whose functions are unknown and which, like the TS genes, occur mostly at subtelomeric locations. Examples of other gene families with more than 10 members also present in the *T. cruzi* genome include glycosyltransferases, protein kinases and phosphatases, kinesins, amino acid transporters and helicases, in addition to several gene families encoding hypothetical proteins ([@b40-gmb-35-1-1]). The collapse of nearly identical repeats in some gene families, such as the gene cluster encoding α- and β-tubulins, meant that not all copies of the family were included in the original genome assembly.

[@b4-gmb-35-1-1] described an analysis of the total genomic repetitive content of protein coding sequences and concluded that 18% of all protein coding sequences existed in 14 or more copies. In addition to the need to evade the host immune system, the existence of highly repetitive gene families in the *T. cruzi* genome in which a large number of gene copies can lead to the enhanced expression of various proteins may help to overcome a major problem in this genome, namely, the lack of strong promoters capable of generating high levels of mRNA from single copy genes. It is also likely that many of the striking polymorphisms among *T. cruzi* isolates that are reflected in several epidemiological and pathological aspects of Chagas disease are partly attributable to variability within regions containing gene families. Whole genome comparisons of distinct *T. cruzi* lineages are beginning to improve our understanding of this question.

Soon after the CL Brener genome was completed several groups began sequencing the genome of representative strains of other major *T. cruzi* lineages. As indicated above, the hybrid nature of the CL Brener genome provided data for two genomes, with "Esmeraldo-like" and "non-Esmeraldo" contigs making it possible to distinguish information from *T. cruzi* II and III groups, respectively (see [Table 1](#t1-gmb-35-1-1){ref-type="table"}). Recently, [@b44-gmb-35-1-1] published a draft genome sequence of Sylvio X10, a strain belonging to *T. cruzi* I group, which is the predominant agent of Chagas disease in Central America and in the Amazon. Although rarely isolated from humans in endemic areas in southern countries of Latin America where most cases of Chagas disease with mega-syndromes occur, *T. cruzi* I strains are highly abundant among wild hosts and vectors ([@b134-gmb-35-1-1]; [@b21-gmb-35-1-1]). Thus, the distinct ecological niches occupied by *T. cruzi* I and II strains, together with the fact these strains are highly divergent in terms of phylogenetic analysis, prompted [@b44-gmb-35-1-1] to sequence the genome of a representative of *T. cruzi* I group and to undertake a comparative analysis with the CL Brener genome.

In agreement with previous analyses, the Sylvio X10 genome was estimated to be \~44 Mb in size, *i.e.*, smaller than the CL Brener genome. Indeed, smaller genomes seems to be a general feature of *T. cruzi* I strains ([@b16-gmb-35-1-1]; [@b44-gmb-35-1-1]). As expected, the architectures of the two genomes were very similar, with highly conserved syntenic regions corresponding to the gene-dense "core" of the coding regions organized for long polycistronic transcription. As with the CL Brener genome, the presence of repetitive sequences meant that the Sylvio X10 genome was represented as fragmented contigs. The technical difficulties associated with the assembly of repetitive sequences meant that only about 49% of the generated Sylvio X10 sequence data was incorporated into contigs, leaving 710,109 reads that were not included in the assembly. Consequently, the draft genome of Sylvio X10 was assembled into 7,092 contigs, which is slightly less than the number of contigs reported for the draft genome of CL Brener. The alignment of these contigs to both CL Brener haplotypes showed that the mean nucleotide identity was greater between Sylvio X10 and non-Esmeraldo (98.2%) than between Sylvio X10 and Esmeraldo (97.5%). This finding agrees with previous phylogenetic analyses indicating that sequences from *T. cruzi* I strains are more closely related to *T. cruzi* III (represented by the non-Esmeraldo CL Brener haplotype) than to *T. cruzi* II (represented by the Esmeraldo-like haplotype) ([@b25-gmb-35-1-1]; [@b97-gmb-35-1-1]).

In contrast to the hybrid CL Brener genome, for which the amount of heterozygosity in the core genome was estimated to be 5.5% ([@b40-gmb-35-1-1]), the diploid Sylvio X10 genome was homozygous (\< 0.08% heterozygosity). Most importantly, analysis of the core gene content of CL Brener and Sylvio X10 revealed six open reading frames that were missing in the Sylvio X10 genome. Besides these six genes, estimations based on total sequence reads indicated that several multicopy gene families, including DGF, mucin, MASP and GP63 contained substantially fewer genes in Sylvio X10 than in CL Brener. A 5.9 Mb size difference between the Sylvio X10/1 and CL Brener genomes largely reflected the expansion of these gene families. However, the extent to which these genomic variations are related to strain differences in host preference and the ability to cause Chagas disease remains to be determined.

The advent of next-generation sequencing technologies has ushered in a new era in comparative sequencing by allowing the exploration of a wide range of evolutionary and pathological questions within the *T. cruzi* lineage. Several groups have initiated sequencing analyses of additional *T. cruzi* isolates. A consortium of laboratories funded by the National Institutes of Health/National Institutes of Allergy and Infectious Diseases (NIAID) and the National Human Genome Research Institute (NHGRI) is sequencing *T. cruzi* strains representative of each one of the six main groups, such as Esmeraldo (*T. cruzi* II), 3869 (*T. cruzi* III), Can III (*T. cruzi* IV), NRcl3 (*T. cruzi* V) and Tula cl2 (*T. cruzi* VI) (N. El-Sayed, personal communication). Our laboratory has been involved in the sequencing of another *T. cruzi* I strain (Dm28c) and CL-14, a non-virulent strain that belongs to the *T. cruzi* VI group (S. Teixeira, unpublished). In contrast to CL Brener, BALB/c mice injected with CL-14 trypomastigotes showed no parasitemia but developed high resistance against a lethal challenge with virulent trypomastigotes from the CL Brener or Y strains ([@b67-gmb-35-1-1]). Our goal in this work is to use comparative analyses of the CL Brener and CL-14 genomes to identify potential sequences that can restore the virulence of CL-14 and then test these in transfection protocols.

In addition to investigations of the nuclear genome, several studies have examined the mitochondrial genome of kinetoplastids which contains a mass of concatenated DNA known as kinetoplast DNA (kDNA) that is easily identified near the insertion of the flagellum ([@b18-gmb-35-1-1]). In *T. cruzi,* kDNA consists of a highly structured disk-shaped network of thousands of concatenated mini-circles 0.5--10 kb in size and dozens of concatenated maxicircles 20--40 kb in size. Whereas minicircle sequences are present exclusively in kinetoplastids, maxicircles are the homologues of mtDNA molecules found in other eukaryotes ([@b68-gmb-35-1-1]). Following publication of the *T. cruzi* genome, [@b123-gmb-35-1-1] described the complete sequences of maxicircle DNAs corresponding to groups *T. cruzi* II (from sequences of the Esmeraldo strain) and III (from CL Brener sequences). As with other trypanosomatid mitochondrial genes, sequence analyses showed that *T. cruzi* maxicircle DNA contained frameshift errors in most of its genes that were corrected at the RNA level by a complex U-insertion/deletion process known as RNA editing ([@b48-gmb-35-1-1]). Key elements of this repair process include gRNAs (guide RNAs) which are encoded mainly by minicircles, although a few gRNA sequences are also present in maxicircles. The gRNAs hybridize to the 3′ end of a target message and undertake direct U insertion and deletion by the so-called editosome machinery ([@b109-gmb-35-1-1]).

The complete sequences of the 25 kb *T. cruzi* maxi-circles revealed 18 tightly clustered mitochondrial protein-coding genes and two rRNA genes that were syntenic with previously sequenced maxicircles of *T. brucei* and *Leishmania tarentolae*. Fifteen of the 18 protein-coding genes were edited. Outside the coding region, strain-specific repetitive regions and a variable region that was unique for each strain were identified ([@b123-gmb-35-1-1]). More recently, comparative analyses of the mitochondrial genomes of *T. cruzi* I, II and III were reported after [@b97-gmb-35-1-1] generated the sequence of the coding region of the maxicircle from Sylvio X10. In agreement with the nuclear genomic analysis, phylogenetic analysis of the maxicircle coding regions supported a close evolutionary relationship between *T. cruzi* I and III. Based on their mitochondrial DNA analyses, these authors proposed a model in which an ancestral strain belonging to *T. cruzi* I provided the maxicircle for the progeny of a TcI-TcII hybridization event that resulted in the generation of *T. cruzi* III and *T. cruzi* IV strains. A subsequent 'back-cross' hybridization between *T. cruzi* II and *T. cruzi* III strains resulted in the *T. cruzi* V and VI strains, such as CL Brener, that carry the maxicircle from their *T. cruzi* III ancestor.

Comparative Genomics of Leishmania Species That Cause Distinct Forms of Leishmaniasis
=====================================================================================

*Leishmania spp.* are parasitic protozoa transmitted by the bites of phlebotomine sand flies that are endemic in tropical and subtropical regions worldwide. More than 20 species are responsible for a wide spectrum of diseases, known as leishmaniasis ([@b82-gmb-35-1-1]). Parasites in this genus are classified into two subgenera according to the part of the sandfly gut where colonization and development occur: the subgenus *Leishmania (Leishmania)* consists of parasites with mid and foregut development, whereas the subgenus *Leishmania (Viannia)* consists of parasites that undergo hindgut development ([@b60-gmb-35-1-1]; [@b9-gmb-35-1-1]). Depending on the species of *Leishmania*, infection of humans may result in diverse clinical forms of leishmaniasis with symptoms ranging from self-healing cutaneous lesions (*L. major*/*L. tropica*/*L. mexicana*) to fatal visceral leishmaniasis (*L. donovani*/*L. infantum*/*L. chagasi*). Infection by *Leishmania* can also result in mucosal leishmaniasis (mainly caused by *L. braziliensis*) and diffuse cutaneous leishmaniasis (mainly caused by *L. amazonensis*/*L. guyanensis*/*L. aethiopica*) ([@b35-gmb-35-1-1]). In addition to the species of *Leishmania*, other factors such as the genetic variability of the human host may determine the disease tropism and clinical manifestations in leishmaniasis ([@b14-gmb-35-1-1]; [@b98-gmb-35-1-1]).

The World Health Organization (WHO) estimates that there are over two million new cases of leishmaniasis each year, with more than 360 million people at risk of contracting this disease in 88 countries on five continents (Asia, Africa, Europe, North America and South America) ([www.who.int/tdrdiseases/leish](www.who.int/tdrdiseases/leish)). As part of their life cycle, *Leishmania* spp. alternate between the alimentary tract of the sandfly vector, where they grow as extracellular flagellated promastigotes and differentiate into infective non-dividing metacyclic forms, and the phagolysosome of the vertebrate host macrophages, where they differentiate into aflagellated, replicative amastigotes ([Figure 1](#f1-gmb-35-1-1){ref-type="fig"}). There is no effective vaccine against *Leishmania* and the available therapeutic arsenal is extremely limited ([@b76-gmb-35-1-1]). Thus, completion of the genome sequences of several *Leishmania* species ([@b51-gmb-35-1-1]; [@b89-gmb-35-1-1]) represents a long awaited aspiration for groups involved in the discovery and development of new drugs and vaccine targets.

*Leishmania major* Friedlin was chosen as the *Leishmania* reference strain for the Tri-Tryp genome project. The *L. major* haploid genome (\~32.8 Mb) is distributed among 36 relatively small chromosomes ranging from 0.28 to 2.8 Mb in size ([@b125-gmb-35-1-1]) and was sequenced after shotgun cloning of large DNA fragments derived from chromosomal bands separated in agarose gels. Prior to publication of the Tri-Tryp genome sequence, the complete sequences of chromosomes 1 and 3 from *L. major* were published ([@b83-gmb-35-1-1]; [@b127-gmb-35-1-1]) and an optical map of the entire genome was generated ([@b132-gmb-35-1-1]). In 2007, the complete genomes of two other *Leishmania* species, *L. infantum* and *L. braziliensis*, were also described ([@b89-gmb-35-1-1])*. Leishmania infantum*, also known as *L. chagasi* in Latin America, was chosen as the second *Leishmania* species to have its genome sequenced on the basis of its virulence in animals, transmissibility in sandflies and adaptability to laboratory experimentation ([@b33-gmb-35-1-1]). This species is the causative agent of visceral leishmaniasis, the most serious form of the disease and frequently fatal if left untreated. The New World species *L. braziliensis*, within the subgenus *L. (Viannia*), is the third and most divergent species sequenced. The *L. infantum* and *L. braziliensis* genome sequences were obtained by the whole-genome shotgun approach with five- and six-fold coverage, respectively ([@b89-gmb-35-1-1]). Importantly, the three complete genomes are from strains that cause distinct types of leishmanial diseases, are adapted for maintenance and manipulation in the laboratory and are also frequently used in studies *in vitro* and in animal models of infection ([@b61-gmb-35-1-1]; [@b51-gmb-35-1-1]; [@b33-gmb-35-1-1]). The complete sequences of all three *Leishmania* genomes can be accessed in the Tri-Tryp database; sequencing of the genome from a fourth species (*L. mexicana*) is in progress.

Surprisingly, comparative genomic studies of the three evolutionarily and geographically distinct species, *L. major* and *L. infantum* (Old World species) and *L. braziliensis* (New World species), showed very little divergence among the species in terms of genomic sequence and organization ([@b89-gmb-35-1-1]; [@b70-gmb-35-1-1]), despite a divergence of 20--100 million years within the *Leishmania* genus ([@b68-gmb-35-1-1]). The haploid genome of the three species has an estimated 8,300 genes, with more than 99% of them maintaining synteny in the three *Leishmania* genomes ([@b89-gmb-35-1-1]). As with the other Tri-Tryps, the majority of *Leishmania* genes are annotated as genes of unknown function. Of the 8,300 genes, only 200 were identified as being differentially distributed between the three genomes. The *L. braziliensis* genome possesses 47 genes that are absent from the other two species, while 27 and 5 genes are specific for the *L. infantum* and *L. major* genomes, respectively. Such high conservation in overall genome sequences and genome synteny indicates that the *Leishmania* genome is highly stable and has not undergone large genomic rearrangements during speciation. This finding also suggests that only a few species-specific parasite genes may contribute to differential pathogenesis and tissue tropism ([@b89-gmb-35-1-1]; [@b105-gmb-35-1-1]).

Thus far, the only gene for which there is experimental evidence indicating direct involvement in the differential tropism among *Leishmania* diseases is the A2 locus. Initially identified as an amastigote-specific gene family in *L. donovani*, A2 has been shown to play a major role in parasite virulence and visceralization ([@b131-gmb-35-1-1]). Multiple copies of the A2 gene alternating with a distinct gene termed the A2rel gene are found in the genome of several species of the *L. donovani* group that is responsible for visceral diseases. Although its precise function is still unknown, the product of the A2 gene, an endoplasmic reticulum protein with a large repetitive domain, may be related to the parasite stress response ([@b77-gmb-35-1-1]). In *L. major*, which does not cause visceral leishmaniasis, the A2 gene is a pseudogene and introduction of the *L. donovani* A2 gene into *L. major* enhanced the ability of *L. major* to survive in visceral organs of susceptible BALB/c mice ([@b131-gmb-35-1-1]). More recently, the expression of A2 in *L. tarentolae*, a lizard parasite that is not pathogenic in mammals, significantly increased the infectivity of this species and enhanced its ability to survive in the liver of BALB/c mice ([@b79-gmb-35-1-1]). In addition to experiments suggesting a possible role for the A2 gene in the differential tropism of cutaneous and visceral leishmania parasites, the A2 gene has been used as a promising vaccine candidate and diagnostic antigen ([@b42-gmb-35-1-1]).

Another locus possibly involved in macrophage invasion and that varies considerably among the three *Leishmania* genomes is the GP63 locus. Also known as the major surface protease (MSP), GP63 constitutes a family of surface metalloproteases expressed in all trypanosomatids examined so far ([@b130-gmb-35-1-1]). GP63 sequences identified in the three *Leishmania* genomes and in the *T. cruzi* and *T. brucei* genomes vary in their gene copy number, and this may have implications for differences in the disease phenotype ([@b120-gmb-35-1-1]). A similar conclusion may apply to the amastin multi-gene family that encodes a family of amastigote-specific, highly glycosylated hydrophobic surface proteins also present in *T. cruzi* but which has been greatly expanded in the genus *Leishmania* ([@b111-gmb-35-1-1]; [@b52-gmb-35-1-1]). Interestingly, in the *T. brucei* genome, which does not have an intracellular stage, only two copies of a highly divergent amastin sequence are present ([@b52-gmb-35-1-1]). The identification of these species-specific genes represents an initial step towards the characterization of parasite factors that may determine the specificities of each type of parasitic infection. On the other hand, antigens common to all *Leishmania* species could be used as potential vaccine candidates ([@b89-gmb-35-1-1]). However, apart from differences in gene sequences, it is possible that the distinct clinical manifestations observed in the different parasitic diseases may be a consequence of differential gene expression that occurs throughout the various stages of life cycle in each parasite species.

As discussed above, *Leishmania* genes are arranged in the genome as directional gene clusters that resemble prokaryotic polycistronic transcription units ([@b72-gmb-35-1-1]). This type of gene organization and polycistronic transcription have profound implications on the regulation of gene expression, which must rely on post-transcriptional mechanisms ([@b15-gmb-35-1-1]; [@b84-gmb-35-1-1]; [@b50-gmb-35-1-1]; [@b63-gmb-35-1-1]). Since the dependency on promoter-based transcription initiation mechanisms for the control of mRNA levels is greatly reduced, greater emphasis is placed on post-transcriptional regulatory mechanisms controlling mRNA stability and translation, as well as protein turnover ([@b26-gmb-35-1-1]). Despite significant differences in life stage morphology, biochemical properties and disease phenotypes, comparative gene expression studies have revealed surprisingly few differences in gene expression when mRNA levels in different life-cycle stages or in the same stage but in different *Leishmania* species were compared ([@b89-gmb-35-1-1]). Global interspecies analyses in *L. major* and *L. infantum* have shown that only 10%--12% of differentially expressed genes are unique to each species ([@b95-gmb-35-1-1]; [@b34-gmb-35-1-1]). A more careful examination of the protein expression patterns and the elucidation of regulatory mechanisms will provide unique insights into this important aspect of the parasite's biology. This information will also improve our understanding of the host-parasite interaction and lead to the development of new strategies for contolling leishmaniasis.

Eukaryotic genomes contain an abundance of repeated DNA and some of these repeated sequences are mobile elements. Transposable elements (TEs) are defined as DNA sequences that are able to move from one location to another in the genome and have been identified in all organisms (prokaryotic and eukaryotic) examined so far. TEs can occupy a high proportion of a species' genome. Retroposons, also known as non-long-terminal-repeat (LTR) retrotransposons, are ubiquitous elements that transpose through an RNA intermediate and are found in the genomes of most eukaryotes ([@b51-gmb-35-1-1]; [@b89-gmb-35-1-1]). *Trypanosoma brucei* and *T. cruzi* contain long autonomous retroposons of the ingi clade (Tbingi and L1Tc, respectively) and short nonautonomous truncated versions (TbRIME and NARTc, respectively), as well as degenerate ingi-related retroposons devoid of coding capacity (DIREs) that represent the most abundant transposable elements in these genomes (\< 3% of the nuclear genome).

In contrast, *L. major* contains only remnants of extinct retroposons (LmDIREs) and short nonautonomous heterogenous elements (LmSIDERs). Recently, small degenerate retroposons (\< 0.55 kb) containing the "79-bp signature" known as LmSIDERs (for *s*hort *i*nterspersed *de*generate *r*etroposons) have also been identified in the genomes of *L. major* ([@b51-gmb-35-1-1]), *L. infantum* and *L. braziliensis* ([@b89-gmb-35-1-1]). Unexpectedly, in *L. braziliensis,* the site-specific non-LTR retroposon SLACS/CZAR, which is associated with tandemly repeated spliced leader sequences in an arrangement similar to that of the SLACS or CZAR element in *T. brucei* or *T. cruzi*, respectively, is fully active ([@b1-gmb-35-1-1]; [@b119-gmb-35-1-1]). However, in contrast to the African trypanosome genomes and similar to *L. major* ([@b51-gmb-35-1-1]) and *L. infantum*, no potentially active ingi-related retroposons were detected in the *L. braziliensis* genome ([@b19-gmb-35-1-1]).

Mobile elements are involved in creating mutations and genomic rearrangements and, in many eukaryotes, these effects can be regulated through an RNA silencing mechanism such as RNA interference (RNAi) ([@b101-gmb-35-1-1]; [@b45-gmb-35-1-1]). Since first reported in 1998 ([@b43-gmb-35-1-1]), RNAi has swept through all fields of eukaryotic biology and has proven to be a very useful tool for analyzing gene function in a variety of organisms in which the introduction or expression of short double-stranded RNAs leads to the rapid destruction of cognate mRNAs ([Figure 4A](#f4-gmb-35-1-1){ref-type="fig"}) ([@b85-gmb-35-1-1]). This approach has a number of advantages: it is fast, requires very little sequence information, and reduces the expression of multiple gene copies, an action that is especially advantageous in asexual diploid organisms ([@b59-gmb-35-1-1]; [@b100-gmb-35-1-1]; [@b121-gmb-35-1-1]).

Soon after it was described in *C. elegans*, RNAi was rapidly identified in *T. brucei* ([@b85-gmb-35-1-1]). As discussed below, RNAi has proven to be a powerful new tool for functional genomic studies in *T. brucei.* Unexpectedly, experimental evidence as well as searches of genome databases quickly showed that RNAi is absent in *L. major* and *T. cruzi* ([@b94-gmb-35-1-1]; [@b29-gmb-35-1-1]). It came as a surprise when [@b89-gmb-35-1-1] revealed that the genome of *L. braziliensis* retained key genes involved with RNAi. These authors showed that *L. braziliensis* genome contains orthologs carrying domains characteristic of the Dicer protein as well as genes with the typical argonaute domains PAZ and PIWI, the latter containing conserved amino acid residues that are essential for functional TbAGO1 ([@b99-gmb-35-1-1]). In addition, an N-terminal RGG domain, present in TbAGO1 and shown to be essential for its association with polyribosomes, is also present in the *L. braziliensis* Ago1 gene ([@b99-gmb-35-1-1]). More recently, [@b69-gmb-35-1-1] demonstrated that the RNAi pathway is functional in *L. braziliensis* and in other species within the *Leishmania* subgenus *Viannia* (*L. guyanensis and L. panamensis*) ([Figure 4B](#f4-gmb-35-1-1){ref-type="fig"}). Thus, this divergent species of *Leishmania* appear to have retained not only the mechanisms for (RNAi)-mediated regulation but also potentially active retroposons ([@b89-gmb-35-1-1]), which might have assisted to create the greater divergence within the *L. braziliensis* genome compared with the other *Leishmania* species. For molecular parasitologists, these findings came as very good news since, as shown in *T. brucei*, the efficacy of RNAi knockdown as a tool for systematic analysis of gene function is now also applicable in some species of *Leishmania.*

Functional Genomics of T. Brucei and Gene Expression Studies in a High Throughput Era
=====================================================================================

Infection by *T. brucei* occurs after metacyclic trypomastigotes are injected into the bloodstream by the bite of a tsetse fly. In the mammalian host, the parasite differentiates into long slender trypomastigotes (bloodstream form -BSF) that divide, colonize the body fluids and can transform into a nonproliferative bloodstream form, also known as the short stump form. After a blood meal, trypomastigotes acquired by the insect vector differentiate into procyclic trypomastigotes in the gut, replicate and then migrate to salivary glands where they transform into metacyclic trypomastigotes ([@b75-gmb-35-1-1]) ([Figure 1](#f1-gmb-35-1-1){ref-type="fig"}). The ability of the BSF to invade the central nervous system leads to the neurological manifestations associated with sleeping sickness.

In contrast to *T. cruzi* and *Leishmania*, *T. brucei* develops extracellularly throughout its entire life cycle. Its direct exposure to a strong antibody response in the bloodstream requires a sophisticated immune evasion protocol, known as variant surface protein (VSG) switching ([@b88-gmb-35-1-1]). VSGs are bloodstream-specific surface proteins with a hypervariable N-terminal domain that is exposed extracellularly and a more conserved C-terminal domain buried in the parasite's surface coat ([@b114-gmb-35-1-1]; [@b113-gmb-35-1-1]). Since they are tightly packed at the surface, VSGs are able to shield other invariant surface proteins from attack by the immune system. The tactic for evasion is based on antigenic variation in which the expression of a specific VSG is replaced by another gene from a supply of almost thousand copies at a rate of approximately one event per 100 cell divisions ([@b114-gmb-35-1-1]; [@b113-gmb-35-1-1]). VSG genes are thus a family of *T. brucei*-specific genes whose monoallelic expression distinguishes African trypanosomes from the other two groups of pathogenic trypanosomatids; the lack of antigenic variation in *T. cruzi* and *Leishmania* spp. means that these species must evade the host's immune system by entering and multiplying inside host cells.

After completion of the *T. b. brucei* genome, it was found that of the 9,068 predicted genes, including 904 pseudogenes, there were 1,700 *T. brucei*-specific genes, 806 of them (or 9% of the whole genome) corresponding to VSGs ([@b41-gmb-35-1-1]). Several VSG genes occur within hundreds of mini-chromosomes (50--150 kb in size) that are also part of the *T. brucei* genome. Surprisingly, analyses of all VSG sequences showed that only 57 are fully functional genes and have all the recognizable features of a typical VSG ([@b12-gmb-35-1-1]). It has been long known that VSG variability can be generated in *T. brucei* by creating mosaic genes that include pseudogenes ([@b96-gmb-35-1-1]). Besides producing variability in VSG epitopes, these rearrangements may have the capacity to generate protein with new functions, as in the case of the SRA gene discussed below ([@b115-gmb-35-1-1]).

As part of their "life in the bloodstream", African trypanosomes that are pathogenic to humans have developed a mechanism to withstand other types of attack from the host immune system. In contrast to *T. brucei brucei*, which do not infect humans, *T. b. gambiense* and *T. b. rhodesiense* are resistant to trypanolytic factors (TLF) present in normal human serum (NHS). TLF activity has been attributed to apolipoprotein L1 (ApoL1) and haptoglobin (Hp)-related protein found in high density lipoprotein (for a review, see [@b124-gmb-35-1-1]). NHS resistance in *T. b. rhodesiense* is conferred by a truncated VSG known as serum resistance associated (SRA) protein which is located in endosomes and binds and neutralizes TLF ([@b31-gmb-35-1-1]; [@b32-gmb-35-1-1]; [@b115-gmb-35-1-1]; [@b90-gmb-35-1-1]; [@b124-gmb-35-1-1]). *Trypanosoma b. gambiense* lacks the SRA gene but still infects humans. The killing of *T. b. brucei* requires the binding of TLF-1 and trafficking to the parasite acidic lysosome. It has been proposed that, in *T. b. gambiense*, changes in the receptor that binds TLF, as well as decreased expression of this gene, are responsible for the resistance of this *T. brucei* sub-species to attack by the human innate immune system ([@b55-gmb-35-1-1]).

Since *T. b. brucei* is harmless to humans and *T. b. gambiense* is the most clinically relevant subspecies, [@b53-gmb-35-1-1] sequenced the genome of *T. b. gambiense* using the whole-genome shotgun approach combined with bacterial artificial chromosome large insert sequencing. Comparison of the sequences from a draft genome assembly of 281 contigs (\~22.1 Mb) with the *T. b. brucei* genome data ([@b12-gmb-35-1-1]) revealed a very similar composition in terms of gene content, gene synteny and sequence identity (86.4% of *T. b. gambiense* coding sequences vary by \< 1% from their orthologs in *T. b. brucei*). Even though these subspecies behave differently in humans, there were very few differences in their genomes. One of these differences involved a gene encoding a putative iron-ascorbate oxidoreductase that is specific to a few *T. b. brucei* strains and is also absent in other trypanosomatids (*L. major* and *T. cruzi*). Thus, it seems that not only differences in gene content *per se*, but also individual single nucleotide polymorphisms (indels) and variations in gene expression, or a combination of these factors, may contribute to this phenotypic variation ([@b53-gmb-35-1-1]).

Coordinated changes in gene expression are vital for trypanosomes since they must deal with rapid changes in their environment (nutrient availability, temperature, host defenses, the presence of drug, etc.) and be able to disseminate by alternating through different hosts. In addition, unique mechanisms for regulating gene expression are required since there is an almost complete absence of transcriptional control at the level of initiation. The lack of transcriptional regulatory elements, including a typical RNA polymerase II promoter, led to the conclusion that most factors involved in controlling gene expression act at the post-transcriptional level. By using approaches such as differential display, RNA fingerprinting, differential screening of cDNA libraries, random sequencing of cDNA clones and DNA microarrays, several groups have shown that significant changes in mRNA levels occur during the life cycle of all Tri-Tryps ([@b111-gmb-35-1-1]; [@b39-gmb-35-1-1]; [@b74-gmb-35-1-1]; [@b37-gmb-35-1-1]; [@b24-gmb-35-1-1]; [@b54-gmb-35-1-1]). Experimental evidence also indicates that, in addition to mRNA stability, changes in polysomal mobilization constitute an important mechanism for regulating gene expression ([@b2-gmb-35-1-1]). With the advent of next generation sequencing technologies such as RNAseq, a global description of gene expression patterns in *T. brucei* has finally been achieved ([@b57-gmb-35-1-1]; [@b86-gmb-35-1-1]; [@b103-gmb-35-1-1]; [@b117-gmb-35-1-1]). This approach has provided much more complete information about mRNA structure and expression levels, including the patterns of spliced leader (SL) and poly-A additions, as well as alternative pre-mRNA processing. Moreover, these global gene expression analyses have confirmed that only two *T. brucei* genes (poly-A polymerase and DNA/RNA helicase) contain introns.

[@b86-gmb-35-1-1] showed that 2,500 alternative splicing events occur during processing of *T. brucei* genes, with a large number of these being regulated during the life cycle (a total of 600 genes have transcripts with more than one trans-spliced variant). The alternative splicing reactions can alter the message dramatically, as shown by [@b86-gmb-35-1-1] and represented in [Figure 3](#f3-gmb-35-1-1){ref-type="fig"}, with changes in the SL addition site leading to alterations in regulatory elements in the 5′UTR (resulting in the modification of gene expression) or the initiator AUG (generating a different N-terminus or even causing a complete change in the translated ORF). Aminoacyl tRNA synthetase transcripts are interesting examples of trans-spliced variants since differences in the enzyme N-terminus result in changes in the protein targeting signal: distinct mRNAs produce proteins that are directed to mitochondria or remain in the cytoplasm ([@b86-gmb-35-1-1]). Likewise, alternative splicing is a potential mechanism for dual localization of the *T. cruzi* LYT1 gene ([@b10-gmb-35-1-1]). In addition to providing a mechanism for generating changes in the proteome, such flexibility in the selection of splicing sites is compatible with evidence that polycistronic transcription may also initiate at internal sites in gene clusters since correct processing of the 5′ end of mRNA can occur at various points in the primary transcript ([@b57-gmb-35-1-1]).

The mechanisms involved in transcription initiation in trypanosomes have always been an intriguing question. Recently, chromatin immunoprecipitation in combination with conventional Sanger sequencing ([@b93-gmb-35-1-1]) or next-generation sequencing technology ([@b102-gmb-35-1-1]; [@b112-gmb-35-1-1]; [@b129-gmb-35-1-1]) has provided a much awaited analysis of the distribution patterns of modified histones throughout the *T. brucei* genome. As summarized in [Figure 3](#f3-gmb-35-1-1){ref-type="fig"}, the divergent strand-switch regions (SSR) have been found to contain an enrichment of histone variants (H2AZ and H2BV), acetylated histone 4 at lysine 10 (H4K10ac), histone 3 acetylated at residues K9 and K14 and trimethylated at K4, the bromodomain factor BDF3, and the transcription factors TRF4 and SNAP50 ([@b93-gmb-35-1-1]; [@b102-gmb-35-1-1]; [@b112-gmb-35-1-1]; [@b129-gmb-35-1-1]). The histone variants H3V and H4V are present at transcription termination sites ([@b102-gmb-35-1-1]). Similar patterns of chromatin modifications from transcription start sites (TSS) located at the beginning of polycistronic units were also found internally in the same polycistronic unit, suggesting the presence of internal TSS, in agreement with RNAseq data ([@b102-gmb-35-1-1]; [@b57-gmb-35-1-1]; [@b129-gmb-35-1-1]).

The increasing number of published genomes and transcriptomic data, partly as a consequence of the introduction of new sequencing platforms, has created enormous challenges for the field of functional genomics. One of the most useful techniques that has been used to identify gene function in *T. brucei* is a combination of the inducible system mediated by T7 RNA polymerase and the tetracy-cline repressor ([@b126-gmb-35-1-1]) in combination with RNAi gene knockdown. As indicated before, in contrast to *T. cruzi* and *L. major*, RNAi is functional in *T. brucei* ([@b85-gmb-35-1-1]; [@b94-gmb-35-1-1]; [@b29-gmb-35-1-1]; [@b69-gmb-35-1-1]). The first large scale functional genomics study using RNAi was reported by [@b81-gmb-35-1-1], who transfected *T. brucei* procyclic forms with a random RNAi library. This library was generated by using a construct to inducibly express dsRNA via two head-to-head tetracycline-regulated T7 RNA polymerase promoters. By selecting parasites that expressed the dsRNA but were unable to bind lectin, these authors identified clones with a reduced glycosylation of surface proteins and showed that these clones had lower expression of hexokinase ([@b81-gmb-35-1-1]).

A few years later, the functions of 197 ORFs from *T. b. brucei* chromosome I were tested by RNAi. RNAi-induced parasites were tested for growth, nuclear and kinetoplast abnormalities by DAPI staining, and a pleio-tropic phenotype, morphology and motility. At least one of these phenotypes was found in 68 individual knockdowns ([@b110-gmb-35-1-1]). In a similar approach, [@b92-gmb-35-1-1] identified novel components of the para-flagellar rod (PFR) structure by comparing proteomic profiles before and after ablating the expression of individual PFR proteins. The silencing of PFR1 and PFR15 was evaluated by two-dimensional difference gel electrophoresis, and the spots with a two-fold change in volume were subjected to tandem MS protein identification. Proteomic analysis combined with RNAi knockdown led to the identification of 30 proteins as potential PFR components, 20 of which were novel proteins. High-throughput cloning systems also enhance functional analyses. By using the Gateway^®^ technology to create yeast two-hybrid vectors, eight non-redundant protein-protein interactions were detected among proteins with a PFR structure ([@b58-gmb-35-1-1]). These authors were able to construct a map showing the complex interaction of PFR proteins.

The availability of efficient methods for genetic manipulation and for testing gene function through RNAi knockdown has led to major advances in genomic, transcriptomic and proteomic analyses of *T. brucei*, and has made this species a model organism for studying basic aspects of trypanosomatid biology. More recently, with the discovery of functional RNAi machinery in *L. braziliensis* and other *Leishmania* species, gene function studies can now be conducted in this group and will soon provide valuable new information about *Leishmania*-specific genes. However, as is becoming increasingly apparent from the data generated by comparative genomic analyses, each of the trypanosomatid species has its peculiarities. Researchers thus face the challenge of developing new protocols specific for studying each parasite and its corresponding diseases. With our current knowledge of each Tri-Tryp disease and the new research methods that are being developed we can expect many new studies to emerge from hypotheses based on the Tri-Tryp genomic data. As a consequence of these new findings, better methods of controlling and preventing these diseases will follow.

The work from SMT and RMCP was funded by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), Instituto Nacional de Ciencia e Tecnologia de Vacinas (INCTV) and the Howard Hughes Medical Institute (HHMI). The work from WDR and MMKM was supported by FAPEMIG, Fundação Araucária de Apoio ao Desenvolvimento Científico e Tecnológico do Paraná (Fundação Araucária), CAPES/Reuni, PPSUS/MS and CNPq.

![The Tri-Tryp life cycles. Representation of the life cycles of *Leishmania major*, *Trypanosoma cruzi* and *T. brucei*, the etiological agents of leishmaniasis, Chagas disease and sleeping sickness, respectively, are shown, with the parasitic forms that are present in the insect vectors and the mammalian hosts. *Leishmania major* proliferates as promastigotes (P) in the sand fly midgut. The parasite is transmitted during bites by this fly and invades mammalian macrophages in the metacyclic promastigote (M) form. Inside the cell, the M form is converted into amastigotes (A) and divides before been released during cell lysis. *Trypanosoma cruzi* replicates as epimastigotes (E) in the reduviid bug midgut and develops into infective metacyclic trypomastigotes that are excreted in the feces (M) and invade different cell types when in contact with the mammalian host. After differentiation into proliferative amastigotes (A), these are transformed into bloodstream trypomastigotes (T) that cause cell lysis and invade new cells. *Trypanosoma brucei* differentiates from procyclic (P) to epimastigote (E) proliferative forms in the tsetse fly before being transformed into infective, metacyclic forms (M) in the salivary glands. After being injected into the host during a blood meal, M forms differentiate into long slender forms (L) that proliferate in the bloodstream and can reach the central nervous system. After increase of parasite numbers these last forms are replaced by non-proliferative stumpy forms (S).](gmb-35-1-1-gfig1){#f1-gmb-35-1-1}

![Gene organization in the Tri-Tryp genome. Panel A shows the gene distribution in a 0.8 Mb region of *T. brucei* chromosome V with eight large polycistronic transcription units (blue arrows: plus strand encoded open reading frames or ORFs; red arrows: minus strand encoded ORFs). In panel B, a genomic region at around 960 kb is magnified to show the gene synteny in the genomes of various trypanosomatids (blue and red boxes correspond to + and − strand-encoded ORFs, respectively). The orange line in both panels corresponds to the chromosome position. Sequence information used to draw panel A and the graphic representation in panel B were obtained from the Tri-Tryp database ([@b5-gmb-35-1-1]).](gmb-35-1-1-gfig2){#f2-gmb-35-1-1}

![Gene expression in trypanosomatids. Large clusters of unrelated genes (arrow boxes) are organized as polycistronic transcription units (PTUs) that are separated by divergent or convergent strand-switch regions. RNA Pol II transcription start sites (TSS) are usually located upstream of the first gene of the PTU ([@b72-gmb-35-1-1]) or can be located as an internal TSS ([@b57-gmb-35-1-1]). At the TSS (large bent arrow), the histone variants H2AZ and H2BV ([@b102-gmb-35-1-1]), modified histones \[K9/K14 acetylated and K4 tri-methylated histone ([@b93-gmb-35-1-1]; [@b112-gmb-35-1-1]; [@b129-gmb-35-1-1]) and K10 acetylated histone H4 ([@b102-gmb-35-1-1])\], bromodomain factor BDF3 ([@b102-gmb-35-1-1]) and transcription factors TRF4 and SNAP50 ([@b112-gmb-35-1-1]) are frequently associated, with a few of these chromatin modifications also detected at internal TSS (small bent arrow) ([@b102-gmb-35-1-1]; [@b129-gmb-35-1-1]). The polycistronic RNAs (pre-mRNAs) are individualized in monocistronic mRNAs after the addition of a capped splice leader RNA through a trans-splicing reaction coupled to polyadenylation. These processing reactions are guided by polypyrimidine tracts (PolyPy) that are present in every intergenic region. Mature mRNAs are exported to the cytoplasm where their stability and translation efficiencies are largely dependent on cis-acting elements present in their untranslated region (UTR) ([@b3-gmb-35-1-1]). Transcriptomic analyses also showed that polycistronic pre-mRNAs can suffer alternative RNA processing that may result in changes in the initiator AUG, thereby altering protein translation (A), targeting and/or function (B). Alternative splicing and polyadenylation can also result in the inclusion/exclusion of regulatory elements present in the 5′ UTRs (C) or 3′ UTRs (D), thereby altering gene expression ([@b57-gmb-35-1-1]; [@b86-gmb-35-1-1]; [@b103-gmb-35-1-1]).](gmb-35-1-1-gfig3){#f3-gmb-35-1-1}

![Retention and loss of RNAi genes in trypanosomatids. (A) Schematic representation of the mechanism of RNA interference (RNAi) present in some trypanosomes. Double-stranded RNA (dsRNA) derived endogenously or by transfection procedures is processed by an RNase III enzyme known as DICER into small interfering dsRNA molecules (siRNA) 19--23 nt long. siRNAs associate with Argonaute (AGO), the catalytic core of the RISC (RNA-induced silencing complex), with one siRNA strand being released and the guide siRNA strand then mediating the degradation or inhibiting the translation of the target mRNA. Genes encoding components of the RNAi machinery occur only in *T. brucei* and in a sub-group of *Leishmania*. (B) Phylogenetic analysis of trypanosomatid species based on the predicted protein sequences of the housekeeping gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and ubiquitin. The neighbor-joining tree was generated using sequences found in the parasite genome databases ([www.genedb.org](www.genedb.org)) and MEGA4 software. The absence or presence of genes encoding components of active RNAi machinery (as identified by [@b69-gmb-35-1-1]) is indicated on the right.](gmb-35-1-1-gfig4){#f4-gmb-35-1-1}

###### 

Classification of *T. cruzi* strains.

  Current designation[a](#tfn2-gmb-35-1-1){ref-type="table-fn"}   Equivalence to former classifications[b](#tfn3-gmb-35-1-1){ref-type="table-fn"}   Examples of representative strains
  --------------------------------------------------------------- --------------------------------------------------------------------------------- ------------------------------------
  *T. cruzi* I                                                    *T. cruzi* I/DTU I                                                                Sylvio X-10, Dm28c
  *T. cruzi* II                                                   *T. cruzi* II/DTU IIb                                                             Esmeraldo, Y
  *T. cruzi* III                                                  *T. cruzi* III/DTU IIc                                                            CM17
  *T. cruzi* IV                                                   DTU IIa                                                                           CanIII
  *T. cruzi* V[c](#tfn4-gmb-35-1-1){ref-type="table-fn"}          DTU IId                                                                           SO3
  *T. cruzi* VI[c](#tfn4-gmb-35-1-1){ref-type="table-fn"}         DTU IIe                                                                           CL Brener

DTU = discrete typing unit.

[@b135-gmb-35-1-1],

[@b80-gmb-35-1-1] (*T. cruzi* I and II classification), [@b20-gmb-35-1-1] (DTU I, IIa-e), [@b30-gmb-35-1-1] (*T. cruzi* I, II and III),

Hybrid strains.

[^1]: Associate Editor: Carlos F.M. Menck
